Waters Acquires Charge Detection Mass Spectrometry Technology to Broaden its Application in Cell and Gene Therapy
News Summary:
Waters has acquired technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry (CDMS).
CDMS overcomes limitations of conventional mass spectrometry in characterizing complex large molecules in cell and gene therapies.
CDMS technology will be further developed to extend capabilities of Waters' mass spectrometry portfolio for broader set of applications and potential customers.
Waters Corporation (NYSE:WAT) today announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry (CDMS)
